Prosthetic joint infection (PJI) - Market Insights, Epidemiology, and Market Forecast-2030

‘Prosthetic joint infection (PJI) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Prosthetic joint infection (PJI), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Prosthetic joint infection (PJI) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted PJI symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Prosthetic joint infection (PJI) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Prosthetic joint infection (PJI) Disease Understanding and Treatment Algorithm

Prosthetic joint infection (PJI) Overview

Prosthetic joint infection (PJI), also known as peri-prosthetic infection is defined as an infection involving the joint prosthesis and adjacent tissue. It is one of the significant complications and etiologies of implant failure after joint replacement and associated with a substantial financial burden on the healthcare system, and significant physical and psychological morbidity on patients.

The majority of PJIs occurring within one year of surgery are initiated through the introduction of microorganisms at the time of surgery and this can occur through either direct contact or aerosolized contamination of the prosthesis or periprosthetic tissue. The most common observed microorganism responsible for PJI is S. aureus bacteremia. Along with this, Coagulase-negative staphylococci, Streptococcus species, Enterococcus species, and aerobic Gram-negative bacilli also play an essential role in the infection.

The clinical manifestations of PJI may include pain, swelling in joint or effusion, erythema or warmth around the joint, fever, drainage, or the presence of a sinus tract communicating with the arthroplasty and others. However, pain is observed as the most frequently reported clinical manifestation. The factors which are responsible for PJI are Diabetes mellitus, Rheumatoid arthritis, male gender, smoking, etc. The diagnosis of PJI continues to be a significant challenge in clinical practice.

Prosthetic joint infection (PJI) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Prosthetic joint infection (PJI) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Prosthetic joint infection (PJI) market report gives a thorough understanding of PJI symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PJI symptoms of treatment algorithms and treatment guidelines for PJI symptoms in the US, Europe, and Japan.

A combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and, in some cases, radiographic results can help in the diagnosis of PJI. Twofold is the general approach to PJI diagnosis. First, it must be found whether the joint is infected; second, if PJI is present; the causative microorganism(s) must be identified, and in many of the cases, its antimicrobial susceptibility must be determined.

Prosthetic joint infection (PJI) Epidemiology

The PJI symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The diagnosed prevalent cases of Prosthetic joint infection (PJI) is increasing in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted PJI symptoms epidemiology segmented as the Total prevalence of Arthroplasty, Total prevalence of PJI, Gender-Specific cases of PJI, Causative Microorganism-specific cases of PJI. The report includes the prevalent scenario of PJI symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Prosthetic joint infection (PJI) Epidemiology

The epidemiology segment also provides the Prosthetic joint infection (PJI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of PJI in 7MM countries was estimated to be 58,832 in 2017.

Prosthetic joint infection (PJI) Drug Chapters

The drug chapter segment of the Prosthetic joint infection (PJI) report encloses the detailed analysis of PJI marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Prosthetic joint infection (PJI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Prosthetic joint infection (PJI) Emerging Drugs

Sodium Fusidate: Arrevus
Sodium Fusidate (Arrevus) is the only member of a unique class of antibiotics, called fusidanes, and has a mechanism of action that differs from any other antibiotic. It is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus strains (MRSA) and interferes with the function of elongation factor G (EF-G), leading to the inhibition of protein synthesis. The product has completed II/III studies for the treatment of PJI and has also received Orphan designation. It has been approved in Europe but never been approved in the US, therefore its approval will lead to a good market share in the US.

Products detail in the report.

Prosthetic joint infection (PJI) Market Outlook

The Prosthetic joint infection (PJI) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Prosthetic joint infection (PJI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Prosthetic joint infection (PJI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Prosthetic joint infection (PJI) market in 7MM is expected to grow in the study period 2017-2030.

The current therapeutic landscape in the 7MM of PJI usually requires combined medical-surgical strategies, including open or arthroscopic debridement without removal of the prosthesis, resection of the prosthesis with or without reimplantation either at the time of removal or delayed by weeks to months. Further arthrodesis, amputation, or antimicrobial suppression without surgery are also recommended.

Antimicrobial therapy should be pathogen directed and guided by the results of antimicrobial susceptibility testing, where applicable. General principles for antimicrobial treatment apply, with priority given to the least toxic, most efficacious, narrow-spectrum antimicrobial regimen.

The generally used antibiotics are Cefazolin, Rifampin, Ciprofloxacin, Vancomycin, Penicillin, Ceftriaxone, Ampicillin, Gentamicin, Clindamycin, and others. These antibiotics may be used as monotherapy or combination therapy depending on the type of microorganisms

Key Findings

This section includes a glimpse of the Prosthetic joint infection (PJI) market in 7MM. The market size of PJI in the seven major markets was found to be USD 57.69 million in 2017.

The United States Market Outlook

This section provides the total Prosthetic joint infection (PJI) market size and market size by therapies in the United States.

The United States accounts for the highest market size of PJI in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Prosthetic joint infection (PJI) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Given the heterogeneous nature of prosthetic joint infections, there are no large randomized control trials to guide recommendations. Surgical strategies differ significantly worldwide; exchange procedures are the favored treatment modality in Northern America, whereas debridement and retention are more commonly performed in Europe. One-stage or direct arthroplasty exchange - preferred more in Europe; Two-stage arthroplasty exchange - preferred more in the US.

Japan Market Outlook

The total Prosthetic joint infection (PJI) market Size and market Size by therapies in Japan are also mentioned.

Prosthetic joint infection (PJI) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Prosthetic joint infection (PJI) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Prosthetic joint infection (PJI) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Prosthetic joint infection (PJI) key players involved in developing targeted therapeutics.

Major players include Arrevus, TenNor Therapeutics, Peptilogics and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Prosthetic joint infection (PJI) emerging therapies.

Reimbursement Scenario in PJI

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

The government is the primary payer for the majority of PJI cases, through Medicare spending. In addition to improving patient outcomes, prevention of PJI may save costs to the Medicare program. Several reimbursements and other strategies are on the horizon that will impact provider compensation for physicians and hospitals

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Prosthetic joint infection (PJI) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Prosthetic joint infection (PJI) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the Prosthetic joint infection (PJI) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of PJI, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
• Comprehensive insight has been provided into the Prosthetic joint infection (PJI) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Prosthetic joint infection (PJI) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Prosthetic joint infection (PJI) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prosthetic joint infection (PJI) market

Report Highlights

• In the coming years, Prosthetic joint infection (PJI) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infection (PJI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for PJI. Launch of emerging therapies will significantly impact the Prosthetic joint infection (PJI) market
• Molecular biology techniques offer the possibility to formulate rapid microbiological identification in the treatment of PJIs

- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Prosthetic joint infection (PJI) Report Insights

• Patient Population
• Therapeutic Approaches
• Prosthetic joint infection (PJI) Pipeline Analysis
• Prosthetic joint infection (PJI) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Prosthetic joint infection (PJI) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage

- Prosthetic joint infection (PJI) Epidemiology Segmentation

• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Prosthetic joint infection (PJI) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What were the Prosthetic joint infection (PJI) Market share (%) distribution in 2017 and how it would look like in 2030?
• What is the trend of arthroplasty cases for joint replacement in the coming years?
• What would be the Prosthetic joint infection (PJI) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Prosthetic joint infection (PJI)market Size during the forecast period (2017-2030)?
• At what CAGR, the Prosthetic joint infection (PJI) market is expected to grow in 7MM during the forecast period (2017-2030)?
• What would be the Prosthetic joint infection (PJI) market outlook across the 7MM during the forecast period (2017-2030)?
• What would be the Prosthetic joint infection (PJI) market growth till 2030 and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the PJI?
• What is the historical Prosthetic joint infection (PJI) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
• What would be the forecasted patient pool of Prosthetic joint infection (PJI) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to PJI?
• Out of all 7MM countries, which country would have the highest prevalent population of Prosthetic joint infection (PJI) during the forecast period (2017-2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Prosthetic joint infection (PJI) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Prosthetic joint infection (PJI) in the USA, Europe, and Japan?
• What are the Prosthetic joint infection (PJI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of PJI?
• How many therapies are developed by each company for the treatment of PJI?
• What is going to be the scenario for PJI treatment for gram negative pathogens? What emerging therapies are targeting gram negative pathogens?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of PJI?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infection (PJI) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Prosthetic joint infection (PJI) and their status?
• What are the key designations that have been granted for the emerging therapies for PJI?
• What are the global historical and forecasted market of PJI?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the Prosthetic joint infection (PJI) market
• To understand the future market competition in the Prosthetic joint infection (PJI) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Prosthetic joint infection (PJI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Prosthetic joint infection (PJI) market
• To understand the future market competition in the Prosthetic joint infection (PJI) market